Organic Active Ingredients TRIZ Cases

Partial D3 agonist and D2 antagonist BP1.4979 preserves CNS therapeutic effects while limiting overstimulation, side effects, and efficacy loss.

Low-nanomolar OGT inhibitors mimic stacked UDP-GlcNAc geometry to block O-GlcNAcylation despite a large, hydrophilic active site.

RNAi suppression of alpha-1 antitrypsin expression reduces mutant protein buildup in hepatocytes to slow AATD liver fibrosis and cirrhosis.

Tumor-associated antigen polypeptides broaden cancer targeting beyond existing antibodies and support more precise diagnosis and therapy.

Small-molecule PD-L1 antagonists replace IV antibodies with oral dosing to cut adverse events, simplify use, and lower manufacturing cost.

Butanetap regulates brain iron and lowers neurotoxic proteins to limit infection-driven neurological damage and plaque formation.

Mixed hydrophobe lengths on one polymer backbone improve amphiphilic control, self-assembly, and adhesive-cohesive balance in solution.

A 1:1:1 gabapentin, ketoprofen, and lysine co-crystal improves solubility and bioavailability to speed pain relief with lower doses.

Targeted heteroaryl and R2 substitutions improve hydantoin MMP-12 inhibitor specificity and potency for elastase-mediated disease treatment.

Hypertonic buffered saline in the vitreous reduces intraretinal cyst severity in XLRS while preserving retinal function and limiting inflammation.

Controlling tasquinimod particle size to D(v,0.9) ≤ 30 μm and D(v,0.5) ≤ 15 μm improves dissolution and oral bioavailability.

A fixed-dose salt combination pairs compound (I) with bile acids to improve cholestatic liver treatment efficacy while avoiding OCA safety limits.

Bacteria that oxidize intestinal cholesterol into 4-C-3 can lower tumor cholesterol and suppress cancer cell growth with fewer side effects.

Combining a VGSC blocker with ionic modulators suppresses tumor invasiveness and metastasis while avoiding the toxicity of high-dose monotherapy.

Novel aryl-imino tryptophan derivatives inhibit cancer cell proliferation and induce apoptosis, reducing tumor burden in cancer models.

Small-molecule NAMPT activators raise NAD+ through the natural biosynthesis pathway, avoiding flushing and toxicity seen with older approaches.

Non-canonical RNA nucleotides raise somatic cell reprogramming and gene editing fidelity while reducing toxicity, mutation risk, and repeat transfections.

LSTA-1 improves drug penetration beyond dense pancreatic tumor stroma, boosting local delivery and response with combination therapy.

Droplet-based particle formation removes solvent without heat or external stress, preserving bioactive substance activity above 80%.

Positively charged starch nanoparticles overcome electrostatic repulsion at carious lesions to retain and deliver calcium and fluoride for remineralization.

Modified trimetazidine redirects cardiac metabolism toward glucose oxidation to improve efficiency and offer a treatment path for HFpEF.

Controlled crystallization into Maribavir Form VI raises synthesis yield to at least 45% while reducing impurities for consistent oral drug quality.

SBEβCD inclusion complexing with bicarbonate boosts meloxicam solubility and absorption, enabling faster migraine relief with rizatriptan.

A viscous, drug-eluting microcapsule implant helps limit surgical blood loss while preventing postoperative adhesions and preserving field access.

Lipid-linked mutant KRAS compounds bind albumin to reach lymph nodes and trigger a stronger immune response for KRAS-driven cancers.

Group I intron self-splicing and IRES-driven circular RNA translation extend protein expression by improving RNA stability in eukaryotic cells.

Pretreated stem cells are driven into migrating neuroblasts to improve nerve regeneration and motor function recovery after spinal cord injury.

A chiral organocatalyst enables stereoselective gamma-lactam synthesis while supporting MAO-B and MSTN inhibition for Parkinson's and muscle disease treatment.

Site-directed covalent IgE blocking uses allergen-targeting moieties and spacers to prevent peanut-triggered degranulation.

Nano- and micromaterial carriers mimic pathogens to block host-cell binding sites, immobilize viruses, and reduce infection spread.

Novel piperazine lipids improve intracellular DNA delivery in lipid nanoparticles while supporting innate immune activation for cancer therapy.

A built-in float spirometer guides consistent inspiratory flow, improving inhaler actuation timing and drug delivery to the lungs.

A pH-dependent coating masks sodium phenylbutyrate taste in the mouth while dissolving in the stomach to preserve bioavailability and compliance.

A vaginal pectin, hyaluronic acid, and collagen composition stimulates local collagen synthesis to relieve atrophy symptoms without systemic absorption risks.

G-rich oligonucleotides form stable G-quadruplexes and use phosphorothioate backbones to resist degradation while inhibiting replication and inflammation.

Engineered gut-colonizing microbes provide sustained L-DOPA delivery to reduce dyskinesia risk while improving Parkinson's symptoms.

Alternating decitabine and 5-azacytidine with tetrahydrouridine limits cytidine deaminase catabolism and improves lung tumor drug exposure.

Synthetic RNA and ion-exchange-treated albumin improve cell transfection while lowering toxicity, mutation risk, and contamination.

Dual EGFR and HER3 binding in a tetravalent antibody helps overcome tumor resistance while strengthening pathway inhibition and ADCC.

Genetic PCSK9 and LDLR profiling guides inhibitor or agonist therapy to limit sepsis severity and help prevent MODS progression.

Aqueous dermal formulation at pH 6-8 improves skin penetration of a basic anti-fibrotic compound while limiting transdermal exposure.

Selective genomic feature modeling improves HRD tumor classification, reduces overfitting, and guides fluorouracil-platinum treatment choices.

Isolating and detecting 4-hydroxymethyl-N-methyl-prolines enables consistent quality control for Zizyphus and Guarana herbal products.

A dexamethasone and triamcinolone acetonide injection sustains COVID-19 symptom relief while reducing side effects and avoiding dose weaning.

Transdermal CBD bypasses gastric degradation and first-pass metabolism to reduce seizures and behavioral symptoms with fewer adverse events.

Targeted hyaluronic acid nanoparticles deliver NOX inhibitors to tumors, reducing healthy tissue damage while improving cancer cell sensitization.

A three-strain Bacteroides consortium boosts IFNγ secretion and strengthens immune checkpoint inhibitor anti-tumor activity in cancer.

Targeted substituent changes on tetrahydrocarbazole compounds push tumor-cell IC50 below 0.2 µM, strengthening their anticancer lead value.

Reduced lurbinectedin dosing with antiemetic prophylaxis helps treat SCLC while controlling thrombocytopenia and extending treatment cycles.

Double-stranded oligonucleotide decoys block transcription factor binding to inhibit breast cancer growth and metastasis with lower toxicity.

A codon-optimized FXN AAV vector with a truncated 3' UTR boosts frataxin and mitochondrial activity while fitting AAV packaging limits.

A stable crystalline Form II converts an unstable amorphous BTK prodrug into a high-purity solid suitable for long-term storage under normal conditions.

Selective TLR7 agonists boost cytokine and interferon responses while minimizing TLR8-driven toxicity in systemic cancer and infection treatment.

A Bacillus, rice bran, L-cysteine, and low-osmolality carbohydrate blend improves glycemic control while avoiding gut microbiome disruption.

A single daily opicapone dose with more frequent levodopa dosing stabilizes plasma levels and reduces Parkinson's wearing-off time.

Specific altritol placement in dsRNA preserves RNAi efficacy while improving nuclease resistance and limiting off-target gene silencing.

Isolated renal cell vesicles are engineered and delivered to improve kidney repair while enabling biomarker-based disease monitoring.

A buccal misoprostol tablet balances hardness with under-60-second disintegration to improve absorption consistency and reduce oral irritation.

Sequential non-polar and polar solvent extraction improves active compound yield and purity from plant biomass while removing contaminants.

Targeted amino acid changes and fatty acid conjugation improve triple-agonist incretin serum stability, receptor activity, and metabolic efficacy.

Modified treprostinil compounds extend half-life for inhaled pulmonary hypertension treatment while reducing toxicity, side effects, and dosing burden.

PROTAC compounds recruit E3 ligases to degrade KAT2A and KAT2B, overcoming limits of conventional modulation in cancer treatment.

An acidic oil-in-water ruxolitinib salt formulation shifts protonation equilibrium to stop dihydrate crystals and keep cream stable at scale.

Crystalline psilocin salts and cocrystals improve aqueous solubility and stability, enabling more precise dosing and faster parenteral onset.

BDSS sequences derived from BCYRN1 sponge miR-138, miR-150, and miR-98 to boost Treg activity and reduce inflammation in immune disorders.

A powder blend of glucomannan, lemon bioflavonoids, and resistant starch improves satiety, insulin sensitivity, and microbiome balance.

A solid-fat budesonide suppository with antioxidant protection stays stable at room temperature while enabling painless rectal delivery.

β-lapachone inhibits fibrosis and inflammation in cholestatic liver disease while reducing liver damage markers with minimal toxicity.

Specific anhydrous radiprodil crystal forms and excipients enable rapid oral dissolution, seizure treatment, and fewer psychotomimetic side effects.

Chiral oligonucleotide modifications improve nuclease stability and cell penetration for selective mutant HTT knockdown in Huntington's disease.

Combining anti-PSGL-1 antibodies with JAK inhibitors drives activated T-cell apoptosis to improve refractory GVHD outcomes.

Immediate- and controlled-release levodopa particles use enteric and muco-adhesive coatings to limit peak-to-trough fluctuations and extend effect.

A modified-release oral minoxidil composition smooths serum peaks, improves absorption consistency, and supports steadier hair-loss treatment.

Targeting VRK2 alongside PD-1 blockade boosts T cell activation, improves tumor clearance, and helps limit inflammatory toxicities.

Linked deferasirox-triapine chelators deplete extracellular and intracellular iron to inhibit cancer growth while sparing normal cells.

Using mesenchymal stem cell membrane-coated liposomes, this case improves kaempferol solubility, liver targeting, and circulation time for ALF treatment.

Terminal phosphorodithioate linkages and ligand conjugation improve oligonucleotide stability, uptake, and target gene silencing in vivo.

iPSC-derived platelets and megakaryocytes enable scalable protein drug loading and targeted delivery while reducing donor dependence and immune risk.

Prodrug pyrazolo-pyrimidines improve oral bioavailability and CNS penetration while preserving PIKfyve inhibition for neurological disease treatment.

A bifunctional compound links c-Myc and other disease proteins to degradation machinery, overcoming poor activity in current inhibition methods.

A lactose-free lurasidone tablet composition uses optimized excipient ratios and film coating to improve dissolution, disintegration, and stability.

Coadministered niacin and tranexamic acid address bleeding and metabolic collapse together, improving survival and blood pressure during hemorrhagic shock.

An anhydrous rapamycin gel uses solvents, hydroxypropyl cellulose, and antioxidants to improve skin penetration while limiting systemic absorption.

Brincidofovir-based glioma therapy improves tumor control and survival, with additive effects alongside temozolomide and lower systemic toxicity.

Specific ErbB3-binding antibodies block resistance-related signaling, reduce tumor growth, and improve combination cancer therapy.

Specific triazolopyrimidine substituents improve microtubule binding consistency, supporting cancer and neurodegenerative disease treatment.

Novel cationic lipid structures and tuned nanoparticle ratios improve nucleic acid delivery efficiency while lowering cytotoxicity and sustaining expression.

Modified prolyl FK506 compounds promote neurite growth and synapse formation while reducing immunosuppressive side effects.

Periodic thyroid beta-agonist dosing induces ABCD2, boosts VLCFA degradation, and lowers C26:0 while limiting drug accumulation.

Icaritin promotes platelet activation and coagulation to limit hemorrhagic transformation and GI bleeding during thrombolytic or antithrombotic treatment.

Multi-step resin adsorption and pH-switched solvent extraction raise mupirocin yield and purity for industrial production.

CRISPR targeting of non-deletional HPFH regions in HSPCs boosts fetal hemoglobin and lowers sickle beta-globin in red blood cells.

Closed TIL expansion with pooled feeders and cryopreservation shortens production time, lowers contamination risk, and supports therapeutic dosing.

Selective esterase treatment removes acetate groups from gellan gum to control acylation and deliver consistent gel texture and setting behavior.

pH-triggered enteric pellets keep melatonin from releasing in the stomach and extend intestinal delivery for sleep maintenance.

By inhibiting CDK6 and DYRK2 in one compound, this case shows a way to curb cancer drug resistance while lowering toxicity.

A CLOCK-binding compound targets a local protein hollow to selectively block CLOCK:BMAL1 interaction and boost circadian rhythm amplitude.

A unit-dose blend of L-ornithine, L-norvaline, agmatine, and herbal extracts boosts nitric oxide and blood flow with a non-prescription approach.

FANA-modified oligonucleotides suppress LINE-1 RNA triggered by heterochromatin loss, helping restore chromatin integrity and reduce aging symptoms.

A DNA-binding protein inside lipid nanoparticles stabilizes large DNA, supports nuclear import, and lowers toxicity during non-viral delivery.